SPEAKER BIOGRAPHIES

Panel 1: Technology Transfer and Licensing

Robert Cook-Deegan, MD, is a professor in the School for the Future of Innovation in Society, and with the Consortium for Science, Policy and Outcomes at Arizona State University. He founded and directed the Duke Center for Genome Ethics, Law and Policy (2002-2012). Prior to Duke, he was with the National Academies of Science, Engineering and Medicine (1991-2002); National Center for Human Genome Research (1989-1990); and congressional Office of Technology Assessment (1982-1988). Cook-Deegan's research interests include science policy, health policy, biomedical research, cancer, and intellectual property. He is the author of "The Gene Wars: Science, Politics, and the Human Genome" and more than 350 other publications. He received his B.A. in Chemistry mcl from Harvard College in 1975 and his M.D. from the University of Colorado in 1979.

Katharine Ku, MS, is the chief licensing advisor in the Palo Alto office of Wilson Sonsini Goodrich and Rosati. She is also a member of the technology transactions and the patents and innovations practice groups. Ku retired in 2018 as executive director of Stanford University's Office of Technology Licensing (OTL), where she had served almost continuously since 1979. During her career, Ku witnessed the emergence, development, and growth of the field of university technology licensing. She highlights technology transfer milestones in which Stanford played a leadership role, including the development of the "Nine Points to Consider in Licensing University Technology" principles. She is an internationally recognized leader in the field of technology transfer. Ku received her M.S. in Mechanical Engineering from Washington University and her B.S. in Chemical Engineering from Cornell University.

Aisling McMahon, LLM, PhD, is a Professor of Law, Maynooth University, Ireland. McMahon joined Maynooth University in 2018, prior to this she was an Assistant Professor in Biolaw and Co-Director of the Centre for Ethics Law and the Life Sciences (CELLS) Durham University, and before this, she was a Lecturer (Assistant Professor) of law at Newcastle University. McMahon is a specialist in health law and intellectual property law. Her research focuses in particular on the regulation of emerging health-technologies and biotechnologies, on the implications of patent rights for access, use and delivery of health-related technologies, and on the role of bioethics within patent grant and licensing decision-making in Europe. She has published widely in leading international journals in these fields, including in the: Medical Law Review, Journal of Medical Ethics, Cambridge Law Journal, Cambridge Quarterly of Healthcare Ethics, and the Journal of Law and the Biosciences.

McMahon holds a PhD in law (University of Edinburgh), Bachelor of Civil Law and LLM (Law, Technology and Governance) degrees from the National University of Ireland Galway.

Panel 2: Decision-Making by Investor Communities

Amitabh Chandra, PhD, MS is the Ethel Zimmerman Wiener Professor of Public Policy and Director of Health Policy Research at the Harvard Kennedy School of Government, and the Henry and Allison McCance Professor of Business Administration at Harvard Business School where he directs the joint MS/MBA program in the life-sciences. Dr. Chandra is a member of the Congressional Budget Office's (CBO) Panel of Health Advisors, and is a Research Associate at the National Bureau of Economic Research (NBER). His research focuses on innovation and pricing in the biopharmaceutical industry, value in health care, medical malpractice, and racial disparities in healthcare. His research has been supported by the National Institute of Aging, the National Institute of Child Health and Development, the Robert Wood Johnson Foundation, and has been published in the American Economic Review, the Journal of Political Economy, the New England Journal of Medicine, the Journal of the American Medical Association, and Health Affairs. He is the Chair Editor of the Review of Economics and Statistics. Dr. Chandra is an elected member of the National Academy of Medicine and the National Academy of Social Insurance.

Fred Cohen, MD, DPhil, is Chair and Chief Investment Officer of Monograph Capital and Co-Founder and Senior Managing Director at Vida Ventures. Prior to Monograph, Cohen was a Partner and founder of TPG Biotechnology, a life science focused investment effort from 2001-2016. From 1980 through 2014, he was at UCSF where he held various clinical responsibilities as a research scientist, an internist for hospitalized patients, a consulting endocrinologist, and as the Chief of the Division of Endocrinology and Metabolism. He received his B.S. degree in Molecular Biophysics and Biochemistry from Yale University, his D.Phil. in Molecular Biophysics from Oxford on a Rhodes Scholarship, his M.D. from Stanford, and his postdoctoral training and postgraduate medical training in Internal Medicine and Endocrinology at UCSF. Cohen has been a member of the National Academy of Medicine since 2004 and the American Academy of Arts and Sciences since 2008.

Sabriya Stukes, PhD, is Chief Scientific Officer at IndieBioNY. She was formerly Operations Director for Stellate Therapeutics, a biotech company developing microbiome-derived therapeutics to treat neurodegenerative diseases. After earning her PhD in Biomedical Sciences from the Albert Einstein College of Medicine, she was the founding Associate Director for the Master's in Translational Medicine (MTM) program at The City College of New York, NYC's first and only graduate degree that educates scientists and engineers in

the hands-on process of medical technology commercialization and healthcare innovation. Stukes' expertise is in working with individuals to identify unmet community needs, design sustainable clinical solutions, think critically about the world around them, and craft compelling scientific narratives. She also has worked for over a decade in fostering equitable and inclusive environments in the STEM disciplines and thinks deeply about how we can build sustainable healthcare solutions that work for all and not just some.